Connor Clark & Lunn Investment Management Ltd. Has $2.69 Million Stock Position in ChromaDex Co. (NASDAQ:CDXC)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in ChromaDex Co. (NASDAQ:CDXCFree Report) by 189.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 506,186 shares of the company’s stock after purchasing an additional 331,014 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.66% of ChromaDex worth $2,685,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Los Angeles Capital Management LLC bought a new position in ChromaDex in the fourth quarter valued at $1,159,000. Raymond James Financial Inc. acquired a new position in shares of ChromaDex during the 4th quarter worth about $818,000. BNP Paribas Financial Markets boosted its stake in shares of ChromaDex by 1,885.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock worth $267,000 after buying an additional 69,582 shares during the last quarter. State Street Corp grew its holdings in shares of ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after acquiring an additional 62,692 shares in the last quarter. Finally, Barclays PLC increased its position in shares of ChromaDex by 322.1% in the third quarter. Barclays PLC now owns 70,072 shares of the company’s stock valued at $256,000 after acquiring an additional 53,472 shares during the last quarter. Institutional investors own 15.41% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on CDXC. LADENBURG THALM/SH SH raised their price target on ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research note on Wednesday, March 5th. StockNews.com cut shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of ChromaDex in a research report on Monday.

Read Our Latest Report on ChromaDex

ChromaDex Stock Up 1.3 %

NASDAQ:CDXC opened at $7.94 on Tuesday. ChromaDex Co. has a 12-month low of $2.31 and a 12-month high of $9.18. The stock’s 50 day moving average price is $6.06 and its two-hundred day moving average price is $5.39. The firm has a market capitalization of $617.34 million, a price-to-earnings ratio of 794.79 and a beta of 2.21.

ChromaDex Company Profile

(Free Report)

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Featured Stories

Want to see what other hedge funds are holding CDXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChromaDex Co. (NASDAQ:CDXCFree Report).

Institutional Ownership by Quarter for ChromaDex (NASDAQ:CDXC)

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.